COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Fixed Versus Flexible Gonadotropin-releasing Hormone (GnRH) Antagonist Initiation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01005784
Recruitment Status : Completed
First Posted : November 2, 2009
Last Update Posted : November 2, 2009
Information provided by:
Aristotle University Of Thessaloniki

Brief Summary:
This is a comparison of pregnancy achievement between two GnRH antagonist protocols which differ in the timing of GnRH antagonist initiation.

Condition or disease Intervention/treatment Phase
Subfertility Drug: Cetrorelix (Cetrotide) Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 146 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fixed Versus Flexible GnRH Antagonist Initiation
Study Start Date : June 2005
Actual Primary Completion Date : January 2008
Actual Study Completion Date : March 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones

Arm Intervention/treatment
Active Comparator: fixed Drug: Cetrorelix (Cetrotide)
fixed antagonist administration on day 6 of ovarian stimulation
Other Name: Cetrorelix, Cetrotide, Serono

Experimental: flexible Drug: Cetrorelix (Cetrotide)
flexible antagonist administration according to specified criteria
Other Name: Cetrorelix, Cetrotide, Serono

Primary Outcome Measures :
  1. Luteinizing hormone rise [ Time Frame: 3-14 days (duration of ovarian stimulation) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 39 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • < 39 years of age
  • BMI 18.5-29.9
  • <= 3 previous IVF cycles

Exclusion Criteria:

  • PCOS
  • Endometriosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01005784

Layout table for location information
Unit for Human Reproduction
Thessaloniki, Greece
Sponsors and Collaborators
Aristotle University Of Thessaloniki
Layout table for investigator information
Principal Investigator: Efstratios Kolibianakis Unit for Human Reproduction
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Prof. Basil Tarlatzis, Medical School, Aristotle University of Thessaloniki Identifier: NCT01005784    
Other Study ID Numbers: UHR-3
First Posted: November 2, 2009    Key Record Dates
Last Update Posted: November 2, 2009
Last Verified: October 2009
Keywords provided by Aristotle University Of Thessaloniki:
GnRH antagonists
Additional relevant MeSH terms:
Layout table for MeSH terms
Genital Diseases, Male
Genital Diseases, Female
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Physiological Effects of Drugs
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists